<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002778</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000064783</org_study_id>
    <secondary_id>P01CA015396</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>JHOC-J9449</secondary_id>
    <secondary_id>BRLX-001.0649</secondary_id>
    <secondary_id>JHOC-94110404</secondary_id>
    <secondary_id>NCI-V96-0900</secondary_id>
    <nct_id>NCT00002778</nct_id>
  </id_info>
  <brief_title>Sargramostim Following Allogeneic Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia</brief_title>
  <official_title>GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR (Rhu-GM-CSF) FOR REDUCTION OF LEUKEMIC RELAPSE AFTER T-LYMPHOCYTE DEPLETED ALLOGENEIC BMT FOR CHRONIC MYELOID LEUKEMIA</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from&#xD;
      dividing so they stop growing or die. Combining chemotherapy with allogeneic bone marrow&#xD;
      transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more&#xD;
      cancer cells. Colony-stimulating factors such as sargramostim may increase the number of&#xD;
      immune cells found in bone marrow or peripheral blood, and may help a person's immune system&#xD;
      recover from the side effects of chemotherapy.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of allogeneic bone marrow transplantation&#xD;
      followed by sargramostim in treating patients who have chronic myelogenous leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine whether the use of sargramostim (GM-CSF) after T-cell depleted, CD34-positive&#xD;
           cell-supplemented allogeneic bone marrow transplantation can reduce leukemic relapse in&#xD;
           patients with chronic myelogenous leukemia.&#xD;
&#xD;
      OUTLINE: Patients receive myeloablation with busulfan and cyclophosphamide on an approved&#xD;
      protocol. Allogeneic bone marrow is harvested and treated in vitro with anti-CD34 antibody.&#xD;
      T-cell depleted, CD34-positive cell-supplemented bone marrow is infused on day 0. Patients&#xD;
      receive high-dose sargramostim (GM-CSF) subcutaneously (SC) beginning on day 5 and continuing&#xD;
      until blood counts recover and then low-dose GM-CSF SC continuing until day 60.&#xD;
&#xD;
      Donor lymphocyte infusions or second unmodified allogeneic bone marrow transplantation&#xD;
      without GM-CSF is considered in case of primary or secondary engraftment failure.&#xD;
&#xD;
      Patients are followed every month for 3 months, every 3 months for 1 year, every 6 months for&#xD;
      1 year, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study within approximately&#xD;
      6-10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    subject accrual and data analysis is completed.&#xD;
  </why_stopped>
  <start_date>February 1995</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>in vitro-treated bone marrow transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of chronic myelogenous leukemia (CML) documented by cytogenetic and&#xD;
             molecular analyses at Johns Hopkins&#xD;
&#xD;
               -  Philadelphia chromosome (Ph)-positive or -negative CML&#xD;
&#xD;
                    -  Ph-negative CML allowed with presence of either:&#xD;
&#xD;
                         -  BCR-ABL rearrangement (on molecular, fluorescent in situ hybridization,&#xD;
                            or polymerase chain reaction analyses)&#xD;
&#xD;
                         -  p210 protein&#xD;
&#xD;
          -  One of the following:&#xD;
&#xD;
               -  Patient age 18 to 65&#xD;
&#xD;
               -  Disease duration longer than 3 years&#xD;
&#xD;
               -  Accelerated phase CML&#xD;
&#xD;
          -  Accelerated phase diagnosis based on any of the following:&#xD;
&#xD;
               -  More than 10% to less than 30% blasts in blood or bone marrow&#xD;
&#xD;
               -  No hematologic response to prior conventional therapy (hydroxyurea or interferon)&#xD;
&#xD;
               -  Extramedullary disease (e.g., progressive splenomegaly or lymphadenopathy)&#xD;
&#xD;
               -  Basophilia greater than 10% in blood or bone marrow&#xD;
&#xD;
               -  Other cytogenetic abnormalities in addition to a single Ph chromosome&#xD;
&#xD;
               -  Second chronic phase&#xD;
&#xD;
          -  Failure on interferon suggested of patients over age 18 with chronic phase CML, with&#xD;
             failure defined as:&#xD;
&#xD;
               -  No detectable Ph-negative metaphases in marrow after 6 months&#xD;
&#xD;
               -  No progressive increase in Ph-negative metaphases in marrow after 6-12 months&#xD;
&#xD;
               -  Less than 50% Ph-negative metaphases after 1 year&#xD;
&#xD;
               -  No complete cytogenetic remission after 2 years&#xD;
&#xD;
               -  Intolerance to interferon therapy&#xD;
&#xD;
          -  No blast crisis CML, chronic myelomonocytic leukemia, or juvenile CML&#xD;
&#xD;
          -  The following conditions are allowed:&#xD;
&#xD;
               -  Leukocyte count abnormalities&#xD;
&#xD;
               -  Fibrosis&#xD;
&#xD;
               -  Anemia&#xD;
&#xD;
               -  Fever or bone pain&#xD;
&#xD;
               -  Thrombocytopenia&#xD;
&#xD;
               -  Bone marrow reticulin&#xD;
&#xD;
          -  Availability of an HLA-identical sibling donor&#xD;
&#xD;
               -  At least 3 years of age (priority given to donors over age 10)&#xD;
&#xD;
               -  Priority given to CMV-negative donor if patient CMV-negative&#xD;
&#xD;
               -  No medical or psychiatric condition that precludes transplant procedure&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 65&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No history of intolerance to sargramostim (GM-CSF)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. Douglas Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 19, 2011</last_update_submitted>
  <last_update_submitted_qc>July 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2011</last_update_posted>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
  <keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

